Claims
- 1. A method of identifying a compound that modulates neuronal plasticity, said method comprising identifying those candidate compounds which modulate association between an Eph receptor or fragment thereof and an ephrin ligand or fragment thereof, or a PDZ protein or fragment thereof and an Eph receptor or fragment thereof,
- 2. The method of claim 1, wherein said PDZ protein is GRIP.
- 3. The method of claim 1, wherein said PDZ protein is a polypeptide that comprises a type II PDZ domain.
- 4. The method of claim 1, wherein said Eph receptor fragment is a C-terminal fragment.
- 5. The method of claim 1, wherein said compound comprises a peptide fragment of GluR2 or Eph receptor.
- 6. The method of claim 1, wherein said modulation is an increase in association.
- 7. The method of claim 1, wherein said modulation is a decrease in association.
- 8. The method of claim 1, wherein said Eph receptor is an EphB receptor.
- 9. A method of screening compounds as potential modulators of neuronal plasticity, said method comprising applying the compounds to postsynaptic neurons of a neuronal synapse and determining whether a biochemical affect is observed at the presynaptic neuron of the synapse.
- 10. The method of claim 9, wherein said biochemical affect is activation of ephrin-B ligands or activation of protein kinase A.
- 11. The method of claim 9, wherein said neurons are from hippocampus, cerebellum, cortico-thalamic or amygdala.
- 12. The method of claim 11, wherein said neurons are hippocampal mossy fiber CA3 neurons.
- 13. A method of screening compounds as potential modulators of neuronal plasticity, said method comprising applying the compounds to postsynaptic neurons of a neuronal synapse and determining clustering of Eph receptors or presynaptic ephrin ligands.
- 14. The method of claim 13, wherein said Eph receptor is an Eph B receptor.
- 15. The method of claim 13, wherein said neurons are from hippocampus, cerebellum, cortico-thalamic or amygdala.
- 16. The method of claim 13, wherein said neurons are hippocampal mossy fiber CA3 neurons.
- 17. The method of claim 13, wherein said clustering is mediated by a PDZ protein or fragment thereof.
- 18. The method of claim 13, wherein said ephrin ligand is an ephrin B ligand.
- 19. Compounds identified by the method of claim 1.
- 20. Compounds identified by the method of claim 9.
- 21. Compounds identified by the method of claim 13.
- 22. A method of modulating neuronal plasticity in an individual in need thereof, said method comprising contacting neurons of the individual with an effective amount of a compound that modulates interaction between Eph receptors on postsynaptic neurons and ephrin ligands on presynaptic neurons.
- 23. The method of 22, wherein said modulation increases long-term potentiation and wherein said compound enhances interaction between Eph receptors with ephrin ligands.
- 24. The method of 22, wherein said modulation decreases long term potentiation and wherein said compound reduces interaction between Eph receptors with ephrin ligands.
- 25. The method of claim 22, wherein said neurons are from hippocampus, cerebellum, cortico-thalamic or amygdala.
- 26. The method of claim 22, wherein said neurons are hippocampal mossy fiber CA3 neurons.
- 27. The method of claim 22, wherein said ephrin ligands are ephrin-B ligands.
- 28. The method of claim 22, wherein said Eph receptors are Eph B receptors.
- 29. A method of modulating neuronal plasticity in an individual in need thereof, said method comprising modulating interaction between Eph receptors on postsynaptic neurons and ephrin ligands on presynaptic neurons.
- 30. The method of 29, wherein said modulation increases long-term potentiation and wherein the interaction between Eph receptors with ephrin ligands is enhanced.
- 31. The method of 29, wherein said modulation decreases long term potentiation and wherein the interaction between Eph receptors with ephrin ligands is reduced.
- 32. The method of claim 29, wherein said neurons are from hippocampus, cerebellum, cortico-thalamic or amygdala.
- 33. The method of claim 29, wherein said neurons are hippocampal mossy fiber CA3 neurons.
- 34. The method of claim 29, wherein said ephrin ligands are ephrin-B ligands.
- 35. The method of claim 29, wherein said Eph receptors are Eph B receptors.
- 36. A method of improving cognition in an individual, said method comprising contacting brain neurons of the individual with an effective amount of a compound that increases clustering of Eph receptors at the synaptic site of postsynaptic neurons or increases clustering of ephrin ligands at the synaptic site of presynaptic neurons.
- 37. The method of claim 36, wherein said neurons are from hippocampus, cerebellum, cortico-thalamic or amygdala.
- 38. The method of claim 36, wherein said neurons are hippocampal mossy fiber CA3 neurons.
- 39. The method of claim 36, wherein said Eph receptors are Eph B receptors.
- 40. A method of improving cognition in an individual, said method comprising increasing clustering of Eph receptors at the synaptic site of postsynaptic neurons or by increasing clustering of ephrin ligands at the synaptic site of presynaptic neurons.
- 41. The method of claim 40, wherein said neurons are from hippocampus, cerebellum, cortico-thalamic or amygdala.
- 42. The method of claim 40, wherein said neurons are hippocampal mossy fiber CA3 neurons.
- 43. The method of claim 40, wherein said Eph receptors are Eph B receptors.
STATEMENT AS TO FEDERALLY-FUNDED RESEARCH
[0001] This invention was supported in part by government funding from the National Institutes of Health under grant no. 5 R01 NS28709-06—10. The United States government may have certain rights in this invention.